Drug intelligence / Profile preview

225Ac-TR2205

Development stage: Phase 1
Lead developer: Tongrui Biopharmaceutical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

225Ac-TR2205 is an experimental targeted alpha-therapy (TAT) radiopharmaceutical being developed for the treatment of advanced metastatic triple-negative breast cancer (TNBC). It consists of the alpha-emitting radioisotope Actinium-225 (225Ac) conjugated to TR2205, a monoclonal antibody that specifically targets Trophoblast cell-surface antigen 2 (TROP2), a protein frequently overexpressed in TNBC. The mechanism of action involves the antibody-mediated delivery of Actinium-225 to tumor cells, where the isotope undergoes decay, emitting high-energy alpha particles. These particles cause lethal double-strand DNA breaks within a short range, effectively killing the cancer cells while sparing distant healthy tissue. The drug is currently undergoing exploratory Phase 1 clinical trials sponsored by Xiaorong Sun to evaluate its safety, tolerability, and dosimetry.

Other names: actinium-225-TR2205actinium225-TR2205actinium 225-TR2205225Ac-TR2205 Injection225Ac-labeled TR2205

Targets

DNATACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on 225Ac-TR2205.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 225Ac-TR2205.

Explore the full profile